CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that the U.S. Food and Drug ...
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- August 7, 2024: Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that the first ...
A phase 1/2 study evaluating the safety and efficacy of autologous TAC T cells in subjects with claudin 18.2+ advanced solid tumors. This is an ASCO Meeting Abstract from the 2025 ASCO ...
SAN DIEGO, Aug. 8, 2024 /PRNewswire/ -- Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that patient dosing has begun for their Phase ...
Angiex, a developer of nuclear-delivered antibody-drug conjugate (ND-ADC) therapies for solid cancers, announced that the first patient has been dosed in the phase 1 clinical trial of AGX101, a novel ...
Kawasaki Gakuen has divulged pyrrole-imidazole polyamides acting as transmembrane 4 L6 family member 1 (TM4SF1) and TMEM132b expression inhibitors reported to be useful for the treatment of cancer ...
AGX101 targets the cancer cells and vasculature of a tumor, and works to eliminate the tumor blood vessels, kill tumor cells capable of invasion or metastasis, and direct the immune system to attack ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results